Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Eitemau Tebyg

• Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
  gan: Craddock, C, et al.
  Cyhoeddwyd: (2017)
• Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
  gan: Craddock, C, et al.
  Cyhoeddwyd: (2017)
• Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
  gan: Craddock, C, et al.
  Cyhoeddwyd: (2013)
• Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
  gan: Craddock, C, et al.
  Cyhoeddwyd: (2013)
• INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
  gan: Goodyear, O, et al.
  Cyhoeddwyd: (2010)